Screener
Bausch + Lomb BLCO Pharmaceuticals — Total revenues
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch + Lomb in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Bausch + Lomb’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001860742-26-000088
| (in millions) | Vision Care / Three Months Ended June 30, 2026 | Vision Care / Three Months Ended June 30, 2025 | Pharmaceuticals / Three Months Ended June 30, 2026 | Pharmaceuticals / Three Months Ended June 30, 2025 | Surgical / Three Months Ended June 30, 2026 | Surgical / Three Months Ended June 30, 2025 | Total / Three Months Ended June 30, 2026 | Total / Three Months Ended June 30, 2025 |
|---|---|---|---|---|---|---|---|---|
| Pharmaceuticals | $1 | $1 | $299 | $259 | — | — | $300 | $260 |
| Devices | 270 | 258 | — | — | 254 | 214 | 524 | 472 |
| OTC | 497 | 482 | — | — | — | — | 497 | 482 |
| Branded and Other Generics | 13 | 10 | 55 | 48 | — | — | 68 | 58 |
| Other revenues | 3 | 2 | — | 2 | 2 | 2 | 5 | 6 |
| $784 | $753 | $354 | $309 | $256 | $216 | $1,394 | $1,278 | |
| Six Months Ended June 30, | ||||||||
| 2026 | 2025 | 2026 | 2025 | 2026 | 2025 | 2026 | 2025 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Bausch + Lomb's pharmaceuticals — total revenues?
- Bausch + Lomb (BLCO) reported pharmaceuticals — total revenues of $300M in Q2 2026.
- How has Bausch + Lomb's pharmaceuticals — total revenues changed year-over-year?
- Bausch + Lomb's pharmaceuticals — total revenues increased by 15.4% year-over-year, from $260M to $300M.
- What is the long-term trend for Bausch + Lomb's pharmaceuticals — total revenues?
- Over 4 years (2021 to 2025), Bausch + Lomb's pharmaceuticals — total revenues has grown at a 21.7% compound annual growth rate (CAGR), from $493M to $1.08B.
- What does pharmaceuticals — total revenues mean?
- Represents the total gross inflow of economic benefits generated from the sale of ophthalmic pharmaceutical products and related services. This is a primary indicator of the segment's market demand, pricing power, and overall commercial success in the vision care industry.
Ask your AI about Bausch + Lomb's pharmaceuticals — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude